Sartorius（0NIR）株式概要ザルトリウス・アクチェンゲゼルシャフトは、バイオプロセス・ソリューション、ラボ製品およびサービスを世界中に提供しています。 詳細0NIR ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長4/6過去の実績4/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より15.6%で取引されている 収益は年間20.69%増加すると予測されています 過去1年間で収益は70.1%増加しました リスク分析多額の負債を抱えている すべてのリスクチェックを見る0NIR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€236.603.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture05b2016201920222025202620282031Revenue €5.4bEarnings €247.5mAdvancedSet Fair ValueView all narrativesSartorius Aktiengesellschaft 競合他社HaleonSymbol: LSE:HLNMarket cap: UK£30.3bHikma PharmaceuticalsSymbol: LSE:HIKMarket cap: UK£3.2bSartorius Stedim BiotechSymbol: ENXTPA:DIMMarket cap: €16.6bEurofins ScientificSymbol: ENXTPA:ERFMarket cap: €11.0b価格と性能株価の高値、安値、推移の概要Sartorius過去の株価現在の株価€236.6052週高値€267.1052週安値€176.20ベータ1.41ヶ月の変化-2.87%3ヶ月変化-0.92%1年変化5.67%3年間の変化-25.92%5年間の変化-41.47%IPOからの変化4,715.06%最新ニュースBuy Or Sell Opportunity • May 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (0.9%).Buy Or Sell Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to €232. The fair value is estimated to be €292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.最新情報をもっと見るRecent updatesBuy Or Sell Opportunity • May 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (0.9%).Buy Or Sell Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to €232. The fair value is estimated to be €292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.Buy Or Sell Opportunity • Feb 09Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at €233. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026Buy Or Sell Opportunity • Nov 14Now 21% undervaluedOver the last 90 days, the stock has risen 14% to €226. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom.New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Buy Or Sell Opportunity • May 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €217. The fair value is estimated to be €277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • May 07Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €226. The fair value is estimated to be €288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.Reported Earnings • Apr 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.Buy Or Sell Opportunity • Mar 26Now 24% undervaluedOver the last 90 days, the stock has risen 1.9% to €219. The fair value is estimated to be €290, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Upcoming Dividend • Mar 21Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 01 April 2025. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (0.7%).Buy Or Sell Opportunity • Mar 04Now 23% undervaluedOver the last 90 days, the stock has risen 3.3% to €222. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin).お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.Reported Earnings • Feb 17Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023)Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Declared Dividend • Feb 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%.お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025Buy Or Sell Opportunity • Jan 16Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €233. The fair value is estimated to be €291, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025Buy Or Sell Opportunity • Dec 16Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.9% to €223. The fair value is estimated to be €286, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 36% per annum over the same time period.お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025Buy Or Sell Opportunity • Nov 15Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €213. The fair value is estimated to be €276, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 37% per annum over the same time period.Reported Earnings • Oct 18Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.Reported Earnings • Jul 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.Buy Or Sell Opportunity • Jul 03Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €210. The fair value is estimated to be €317, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • Jul 02Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to €213. The fair value is estimated to be €321, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • Jul 01Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €213. The fair value is estimated to be €320, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • Jun 19Now 30% undervalued after recent price dropOver the last 90 days, the stock has fallen 43% to €212. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • Jun 13Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to €242. The fair value is estimated to be €306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Buy Or Sell Opportunity • May 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to €240. The fair value is estimated to be €302, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Reported Earnings • Apr 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.Upcoming Dividend • Mar 26Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (0.6%).Declared Dividend • Feb 19Dividend of €0.74 announcedShareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%.Reported Earnings • Feb 17Full year 2023 earnings releasedFull year 2023 results: Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024Buy Or Sell Opportunity • Jan 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €329. The fair value is estimated to be €268, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €231 per share.Reported Earnings • Oct 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €266, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom.Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €218 per share.Reported Earnings • Apr 23First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom.Upcoming Dividend • Mar 23Upcoming dividend of €1.44 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (0.7%).Reported Earnings • Feb 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.Valuation Update With 7 Day Price Move • Jan 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to €423, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 97% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €225 per share.お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 17% share price gain to €391, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 120% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to €402, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €241 per share.株主還元0NIRGB Life SciencesGB 市場7D10.9%1.1%0.5%1Y5.7%-4.6%18.0%株主還元を見る業界別リターン: 0NIR過去 1 年間で-4.6 % の収益を上げたUK Life Sciences業界を上回りました。リターン対市場: 0NIRは、過去 1 年間で18 % のリターンを上げたUK市場を下回りました。価格変動Is 0NIR's price volatile compared to industry and market?0NIR volatility0NIR Average Weekly Movement7.1%Life Sciences Industry Average Movement8.7%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%安定した株価: 0NIR 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0NIRの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト187014,242Michael Grossewww.sartorius.comザルトリウス・アクチェンゲゼルシャフトは、バイオプロセス・ソリューション、ラボ製品およびサービスを世界中に提供しています。同社は、生物層干渉計システム、サイトメトリーシステムによるハイスループットスクリーニング、プロセス分析技術およびデータ分析、細胞選択および回収、ライブセルイメージングおよび分析システム、表面プラズモン共鳴システムなどの分析ソリューション、バイオリアクターおよび発酵槽、細胞培養試薬、サプリメントおよびマトリックス、核酸および送達ソリューション、細胞培養培地、細胞株および緩衝液などの細胞培養ソリューション、および流体管理製品を提供している。また、ラボ用ろ過・浄化ソリューション、ラボ用水浄化システム、マイクロティッシュ技術、ラボ用計量、ピペット、チップ、ディスペンサー、微生物検査ソリューション、ラボ用データ・フリート管理ソフトウェア、OEMソリューション、プロセスクロマトグラフィーおよびろ過ソリューションも提供している。同社はライフサイエンス研究、バイオ医薬品製造、細胞・遺伝子治療、応用産業にサービスを提供している。創業は1870年で、本社はドイツのゲッティンゲンにある。もっと見るSartorius Aktiengesellschaft 基礎のまとめSartorius の収益と売上を時価総額と比較するとどうか。0NIR 基礎統計学時価総額€14.63b収益（TTM）€162.60m売上高(TTM)€3.55b99.9xPER（株価収益率4.6xP/Sレシオ0NIR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0NIR 損益計算書（TTM）収益€3.55b売上原価€1.93b売上総利益€1.62bその他の費用€1.46b収益€162.60m直近の収益報告Mar 31, 2026次回決算日Jul 23, 2026一株当たり利益（EPS）2.36グロス・マージン45.59%純利益率4.57%有利子負債／自己資本比率105.3%0NIR の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.3%現在の配当利回り33%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 02:18終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sartorius Aktiengesellschaft 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Charles PitmanBarclaysCharles PitmanBarclaysSamuel EnglandBerenberg35 その他のアナリストを表示
Buy Or Sell Opportunity • May 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.
Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (0.9%).
Buy Or Sell Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to €232. The fair value is estimated to be €292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
Buy Or Sell Opportunity • May 08Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to €215. The fair value is estimated to be €274, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.
Upcoming Dividend • Mar 20Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 27 March 2026. Payment date: 31 March 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (0.9%).
Buy Or Sell Opportunity • Mar 02Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.4% to €232. The fair value is estimated to be €292, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
Reported Earnings • Feb 17Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.54b (up 4.7% from FY 2024). Net income: €154.9m (up 84% from FY 2024). Profit margin: 4.4% (up from 2.5% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Feb 09Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at €233. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
Buy Or Sell Opportunity • Jan 14Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €254. The fair value is estimated to be €322, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
Buy Or Sell Opportunity • Nov 14Now 21% undervaluedOver the last 90 days, the stock has risen 14% to €226. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom.
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).
お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
Buy Or Sell Opportunity • May 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €217. The fair value is estimated to be €277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • May 07Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €226. The fair value is estimated to be €288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
Reported Earnings • Apr 17First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
Buy Or Sell Opportunity • Mar 26Now 24% undervaluedOver the last 90 days, the stock has risen 1.9% to €219. The fair value is estimated to be €290, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Upcoming Dividend • Mar 21Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 01 April 2025. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (0.7%).
Buy Or Sell Opportunity • Mar 04Now 23% undervaluedOver the last 90 days, the stock has risen 3.3% to €222. The fair value is estimated to be €287, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin).
お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.
Reported Earnings • Feb 17Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023)Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Declared Dividend • Feb 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%.
お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025
Buy Or Sell Opportunity • Jan 16Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 13% to €233. The fair value is estimated to be €291, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.
お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025
Buy Or Sell Opportunity • Dec 16Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 8.9% to €223. The fair value is estimated to be €286, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 36% per annum over the same time period.
お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025
Buy Or Sell Opportunity • Nov 15Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to €213. The fair value is estimated to be €276, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 37% per annum over the same time period.
Reported Earnings • Oct 18Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.
Reported Earnings • Jul 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.
Buy Or Sell Opportunity • Jul 03Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 40% to €210. The fair value is estimated to be €317, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • Jul 02Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to €213. The fair value is estimated to be €321, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • Jul 01Now 34% undervalued after recent price dropOver the last 90 days, the stock has fallen 42% to €213. The fair value is estimated to be €320, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • Jun 19Now 30% undervalued after recent price dropOver the last 90 days, the stock has fallen 43% to €212. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • Jun 13Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 34% to €242. The fair value is estimated to be €306, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Buy Or Sell Opportunity • May 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to €240. The fair value is estimated to be €302, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Reported Earnings • Apr 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.
Upcoming Dividend • Mar 26Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (0.6%).
Declared Dividend • Feb 19Dividend of €0.74 announcedShareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%.
Reported Earnings • Feb 17Full year 2023 earnings releasedFull year 2023 results: Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024
Buy Or Sell Opportunity • Jan 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to €329. The fair value is estimated to be €268, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024
お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €231 per share.
Reported Earnings • Oct 19Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €266, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.
お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.
Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €218 per share.
Reported Earnings • Apr 23First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom.
Upcoming Dividend • Mar 23Upcoming dividend of €1.44 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (0.7%).
Reported Earnings • Feb 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom.
お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
Valuation Update With 7 Day Price Move • Jan 16Investor sentiment improved over the past weekAfter last week's 15% share price gain to €423, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 97% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €225 per share.
お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 17% share price gain to €391, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 120% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.
お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023
お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment improved over the past weekAfter last week's 15% share price gain to €402, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €241 per share.
